Consensus Botanix Pharmaceuticals Limited

Equities

BOT

AU000000BOT2

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-06-17 EDT			5-day change	1st Jan Change
0.33 ^AUD	0.00%		+20.00%	+73.68%

06-12	Botanix Pharmaceuticals Submits Last Label Materials for Sofdra FDA Approval	MT
05-21	Evans & Partners Starts Botanix Pharmaceuticals at Speculative Buy With AU$0.55 Price Target	MT

Evolution of the average Target Price on Botanix Pharmaceuticals Limited

Price target over the last 5 years

History of analyst recommendation changes

1f2552db9c38a19822fb.Uznes8lX21qNvcULKVaa5S4lSKFUP5jhFidLDhbC0vM.ZnuK0KcPlGPp7p1JWQfR0GxPJvQARsHMV2MmT1e74Z5hDbD4pAOfbdnohA~3ba359a224d141da92a11721e9e13bfa

Analyst Recommendations on Botanix Pharmaceuticals Limited

Evans & Partners Starts Botanix Pharmaceuticals at Speculative Buy With AU$0.55 Price Target	05-21	MT
Euroz Hartleys Adjusts Botanix Pharmaceutical’s Price Target to AU$0.33 From AU$0.30, Keeps at Speculative Buy	05-13	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.33 AUD

Average target price

0.55 AUD

Spread / Average Target

+66.67%

High Price Target

0.55 AUD

Spread / Highest target

+66.67%

Low Price Target

0.55 AUD

Spread / Lowest Target

+66.67%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Botanix Pharmaceuticals Limited

Evans & Partners
Euroz Hartleys

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar